文献速递淋巴瘤

纳武利尤单抗联合维布妥昔单抗治疗复发/难治性原发纵隔大B细胞淋巴瘤:II期CheckMate 436研究的疗效与安全性

Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study.
PubMed 文献 · J Clin Oncol · 2019-08-09

CheckMate 436研究扩展队列纳入30例复发/难治性原发纵隔大B细胞淋巴瘤患者,接受纳武利尤单抗联合维布妥昔单抗治疗。中位随访11.1个月,研究者评估客观缓解率73%(95%CI 54%-88%),完全缓解率37%;独立评估客观缓解率70%(95%CI 51%-85%),完全代谢缓解率43%。中位缓解持续时间、无进展生存期和总生存期均未达到。

要点

  • 纳武利尤单抗联合维布妥昔单抗在复发/难治性原发纵隔大B细胞淋巴瘤中显示高抗肿瘤活性。
  • 研究者评估客观缓解率73%,完全缓解率37%;独立评估客观缓解率70%,完全代谢缓解率43%。
  • 治疗相关不良事件发生率为83%,3-4级不良事件发生率为53%,无治疗相关死亡。

核心结论

  • 在复发/难治性原发纵隔大B细胞淋巴瘤患者中,纳武利尤单抗联合维布妥昔单抗具有高抗肿瘤活性和可控的安全性。

研究设计与样本

  • 开放标签I/II期CheckMate 436研究的扩展队列,纳入30例经组织学确认的复发/难治性原发纵隔大B细胞淋巴瘤患者,既往接受过自体造血干细胞移植或≥2线化疗且不适合自体移植。
  • 患者接受纳武利尤单抗240 mg静脉注射联合维布妥昔单抗1.8 mg/kg静脉注射,每3周一次,直至疾病进展或不可接受毒性。
  • 主要终点为研究者根据Lugano 2014标准评估的客观缓解率和安全性。

主要发现

  • 中位随访11.1个月,研究者评估客观缓解率为73%(95%CI 54%-88%),完全缓解率37%。
  • 独立评估客观缓解率为70%(95%CI 51%-85%),完全代谢缓解率43%。
  • 中位缓解持续时间、中位无进展生存期和中位总生存期均未达到。
  • 11例缓解者接受巩固移植,其中自体移植5例,异基因移植6例。

临床怎么用

  • 对于复发/难治性原发纵隔大B细胞淋巴瘤,纳武利尤单抗联合维布妥昔单抗可作为有前景的治疗选择,需关注中性粒细胞减少、血小板减少和周围神经病变等不良事件。

局限性

  • 研究为开放标签、单臂设计,样本量较小(30例),随访时间较短(中位11.1个月),中位缓解持续时间、无进展生存期和总生存期尚未达到。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Primary mediastinal B-cell lymphoma (PMBL) is a rare but aggressive non-Hodgkin lymphoma with poor outcomes in patients with relapsed/refractory (R/R) disease. PMBL is characterized by high expression of programmed death-1 ligand and variable expression of CD30. Nivolumab, an anti-programmed death-1 immune checkpoint inhibitor, and brentuximab vedotin (BV), an anti-CD30 antibody-drug conjugate, may have synergistic activity in R/R PMBL. METHODS: The expansion cohort of the open-label, phase I/II CheckMate 436 study enrolled patients with confirmed R/R PMBL who were previously treated with either autologous hematopoietic cell transplantation or two or more prior chemotherapy regimens if ineligible for autologous hematopoietic cell transplantation. Patients received nivolumab (240 mg intravenously) and BV (1.8 mg/kg intravenously) every 3 weeks until disease progression or unacceptable toxicity. Primary end points were investigator-assessed objective response rate (ORR) per the Lugano 2014 criteria and safety. RESULTS: Thirty patients with PMBL were treated and evaluable. At a median follow-up of 11.1 months, ORR (95% CI) was 73% (54% to 88%), with a 37% complete remission rate per investigator, and ORR of 70% (51% to 85%), with a 43% complete metabolic response rate per independent review. Median duration of response, median progression-free survival, and median overall survival have not been reached. Eleven responders had consolidation with autologous (n = 5) or allogeneic (n = 6) transplantation. Treatment-related adverse events were reported in 25 patients (83%). Sixteen patients (53%) had grade 3 to 4 treatment-related adverse events; the most common were neutropenia (n = 9), thrombocytopenia (n = 3), and peripheral neuropathy (n = 3). There were no treatment-related deaths. CONCLUSION: In patients with R/R PMBL, the combination of nivolumab plus BV represents a promising option, with high antitumor activity and a manageable safety profile.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Zinzani PL, Santoro A, Gritti G, et al. Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study. J Clin Oncol. 2019. PMID: 31398081. doi:10.1200/JCO.19.01492

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。